Cargando…

PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma

The objective was to assess the cost-effectiveness of staging PET/CT in early-stage follicular lymphoma (FL) from the Canadian health-care system perspective. Methods: The study population was FL patients staged as early-stage using conventional CT imaging and planned for curative-intent radiation t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo, Andrea C., James, Lyndon P., Prica, Anca, Raymakers, Adam, Peacock, Stuart, Qu, Melody, Louie, Alex V., Savage, Kerry J., Sehn, Laurie H., Hodgson, David, Yang, Joanna C., Eich, Hans T.T., Wirth, Andrew, Hunink, M.G. Myriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973292/
https://www.ncbi.nlm.nih.gov/pubmed/34413148
http://dx.doi.org/10.2967/jnumed.121.262324
_version_ 1784680017991565312
author Lo, Andrea C.
James, Lyndon P.
Prica, Anca
Raymakers, Adam
Peacock, Stuart
Qu, Melody
Louie, Alex V.
Savage, Kerry J.
Sehn, Laurie H.
Hodgson, David
Yang, Joanna C.
Eich, Hans T.T.
Wirth, Andrew
Hunink, M.G. Myriam
author_facet Lo, Andrea C.
James, Lyndon P.
Prica, Anca
Raymakers, Adam
Peacock, Stuart
Qu, Melody
Louie, Alex V.
Savage, Kerry J.
Sehn, Laurie H.
Hodgson, David
Yang, Joanna C.
Eich, Hans T.T.
Wirth, Andrew
Hunink, M.G. Myriam
author_sort Lo, Andrea C.
collection PubMed
description The objective was to assess the cost-effectiveness of staging PET/CT in early-stage follicular lymphoma (FL) from the Canadian health-care system perspective. Methods: The study population was FL patients staged as early-stage using conventional CT imaging and planned for curative-intent radiation therapy (RT). A decision analytic model simulated the management after adding staging PET/CT versus using staging CT alone. In the no-PET/CT strategy, all patients proceeded to curative-intent RT as planned. In the PET/CT strategy, PET/CT information could result in an increased RT volume, switching to a noncurative approach, or no change in RT treatment as planned. The subsequent disease course was described using a state-transition cohort model over a 30-y time horizon. Diagnostic characteristics, probabilities, utilities, and costs were derived from the literature. Baseline analysis was performed using quality-adjusted life years (QALYs), costs (2019 Canadian dollars), and the incremental cost-effectiveness ratio. Deterministic sensitivity analyses were conducted, evaluating net monetary benefit at a willingness-to-pay threshold of $100,000/QALY. Probabilistic sensitivity analysis using 10,000 simulations was performed. Costs and QALYs were discounted at a rate of 1.5%. Results: In the reference case scenario, staging PET/CT was the dominant strategy, resulting in an average lifetime cost saving of $3,165 and a gain of 0.32 QALYs. In deterministic sensitivity analyses, the PET/CT strategy remained the preferred strategy for all scenarios supported by available data. In probabilistic sensitivity analysis, the PET/CT strategy was strongly dominant in 77% of simulations (i.e., reduced cost and increased QALYs) and was cost-effective in 89% of simulations (i.e., either saved costs or had an incremental cost-effectiveness ratio below $100,000/QALY). Conclusion: Our analysis showed that the use of PET/CT to stage early-stage FL patients reduces cost and improves QALYs. Patients with early-stage FL should undergo PET/CT before curative-intent RT.
format Online
Article
Text
id pubmed-8973292
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Society of Nuclear Medicine
record_format MEDLINE/PubMed
spelling pubmed-89732922022-04-15 PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma Lo, Andrea C. James, Lyndon P. Prica, Anca Raymakers, Adam Peacock, Stuart Qu, Melody Louie, Alex V. Savage, Kerry J. Sehn, Laurie H. Hodgson, David Yang, Joanna C. Eich, Hans T.T. Wirth, Andrew Hunink, M.G. Myriam J Nucl Med Clinical Investigation The objective was to assess the cost-effectiveness of staging PET/CT in early-stage follicular lymphoma (FL) from the Canadian health-care system perspective. Methods: The study population was FL patients staged as early-stage using conventional CT imaging and planned for curative-intent radiation therapy (RT). A decision analytic model simulated the management after adding staging PET/CT versus using staging CT alone. In the no-PET/CT strategy, all patients proceeded to curative-intent RT as planned. In the PET/CT strategy, PET/CT information could result in an increased RT volume, switching to a noncurative approach, or no change in RT treatment as planned. The subsequent disease course was described using a state-transition cohort model over a 30-y time horizon. Diagnostic characteristics, probabilities, utilities, and costs were derived from the literature. Baseline analysis was performed using quality-adjusted life years (QALYs), costs (2019 Canadian dollars), and the incremental cost-effectiveness ratio. Deterministic sensitivity analyses were conducted, evaluating net monetary benefit at a willingness-to-pay threshold of $100,000/QALY. Probabilistic sensitivity analysis using 10,000 simulations was performed. Costs and QALYs were discounted at a rate of 1.5%. Results: In the reference case scenario, staging PET/CT was the dominant strategy, resulting in an average lifetime cost saving of $3,165 and a gain of 0.32 QALYs. In deterministic sensitivity analyses, the PET/CT strategy remained the preferred strategy for all scenarios supported by available data. In probabilistic sensitivity analysis, the PET/CT strategy was strongly dominant in 77% of simulations (i.e., reduced cost and increased QALYs) and was cost-effective in 89% of simulations (i.e., either saved costs or had an incremental cost-effectiveness ratio below $100,000/QALY). Conclusion: Our analysis showed that the use of PET/CT to stage early-stage FL patients reduces cost and improves QALYs. Patients with early-stage FL should undergo PET/CT before curative-intent RT. Society of Nuclear Medicine 2022-04 /pmc/articles/PMC8973292/ /pubmed/34413148 http://dx.doi.org/10.2967/jnumed.121.262324 Text en © 2022 by the Society of Nuclear Medicine and Molecular Imaging. https://creativecommons.org/licenses/by/4.0/Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.
spellingShingle Clinical Investigation
Lo, Andrea C.
James, Lyndon P.
Prica, Anca
Raymakers, Adam
Peacock, Stuart
Qu, Melody
Louie, Alex V.
Savage, Kerry J.
Sehn, Laurie H.
Hodgson, David
Yang, Joanna C.
Eich, Hans T.T.
Wirth, Andrew
Hunink, M.G. Myriam
PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma
title PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma
title_full PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma
title_fullStr PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma
title_full_unstemmed PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma
title_short PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma
title_sort pet-based staging is cost-effective in early-stage follicular lymphoma
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973292/
https://www.ncbi.nlm.nih.gov/pubmed/34413148
http://dx.doi.org/10.2967/jnumed.121.262324
work_keys_str_mv AT loandreac petbasedstagingiscosteffectiveinearlystagefollicularlymphoma
AT jameslyndonp petbasedstagingiscosteffectiveinearlystagefollicularlymphoma
AT pricaanca petbasedstagingiscosteffectiveinearlystagefollicularlymphoma
AT raymakersadam petbasedstagingiscosteffectiveinearlystagefollicularlymphoma
AT peacockstuart petbasedstagingiscosteffectiveinearlystagefollicularlymphoma
AT qumelody petbasedstagingiscosteffectiveinearlystagefollicularlymphoma
AT louiealexv petbasedstagingiscosteffectiveinearlystagefollicularlymphoma
AT savagekerryj petbasedstagingiscosteffectiveinearlystagefollicularlymphoma
AT sehnlaurieh petbasedstagingiscosteffectiveinearlystagefollicularlymphoma
AT hodgsondavid petbasedstagingiscosteffectiveinearlystagefollicularlymphoma
AT yangjoannac petbasedstagingiscosteffectiveinearlystagefollicularlymphoma
AT eichhanstt petbasedstagingiscosteffectiveinearlystagefollicularlymphoma
AT wirthandrew petbasedstagingiscosteffectiveinearlystagefollicularlymphoma
AT huninkmgmyriam petbasedstagingiscosteffectiveinearlystagefollicularlymphoma